European Journal of Clinical Pharmacology

, Volume 26, Issue 1, pp 65–70 | Cite as

The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon

  • N. R. Kitteringham
  • L. Büstgens
  • E. Brundert
  • S. Mineshita
  • E. E. Ohnhaus
Originals

Summary

Phenprocoumon was given orally to 9 patients with biopsy proven liver cirrhosis (dose range 0.12–0.25 mg/kg) and to 7 healthy volunteers (0.23 mg/kg). Concentrations of phenprocoumon were determined using HPLC in plasma and urine samples obtained for 6–7 days after drug administration. The binding of [3H]-phenprocoumon in plasma from all subjects was determined by equilibrium dialysis. Antipyrine plasma concentrations were determined spectrophotometrically following oral administration of antipyrine (1200 mg). The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64±0.16 ml/h/kg mean ± SEM) than in the healthy volunteers (0.90±0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144±14 ml/h/kg) compared with normal (113±11 ml/h/kg). In contrast the clearance of antipyrine was much reduced in the cirrhotic group (17.5±2.9 ml/h/kg) compared with normal (35.6±3.9 ml/h/kg). The metabolic clearance of phenprocoumon via glucuronidation, is relatively unaffected during cirrhosis compared with antipyrine clearance via oxidation.

Key words

phenprocoumon liver cirrhosis metabolic clearance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreasen PB, Ranek L, Statland BE, Tygstrup N (1974) Clearance of antipyrine. Dependence of quantitative liver function. Europ J Clin Invest 4: 129–134Google Scholar
  2. Brodie BB, Axelrod J, Soberman R, Levy BB (1949) The estimation of antipyrine in biological materials. J Biol Chem 179: 25–29Google Scholar
  3. Heni G, Lehnhardt G, Glogner P (1976) Eliminationkinetik von Phenprocoumon (Marcumar) bei Leberzirrhose und nach Vorbehandlung mit Phenobarbital. Int J Clin Pharmacol 13: 253–261Google Scholar
  4. Kitteringham NR, Büstgens L, Brundert E, Mineshita S, Ohnhaus EE (1983) Pharmacokinetics of phenprocoun in patients with liver cirrhosis. Br J Clin Pharmacol 15: 590 PGoogle Scholar
  5. Klotz U, Fischer C, Müller-Seydlitz P, Schulz J, Müller WA (1979) Alterations in the disposition of differently cleared drugs in patients with cirrhosis. Clin Pharmacol Ther 26: 221–227Google Scholar
  6. Koch-Weser J, Sellers EM (1971) Drug interactions with coumarin anticoagulants. New Engl J Med 285: 487–498Google Scholar
  7. Kraus JW, Desmond PV, Marshall SP, Johnson RF, Schenker S, Wilkinson GR (1978) Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 24: 411–419Google Scholar
  8. Meinertz Th, Gilfrich HJ, Groth U, Jonen HG, Jähnchen E (1977) Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther 21: 731–735Google Scholar
  9. Ohnhaus EE, Münch U, Meier J (1976) Vergleichende Untersuchung zur Elimination von Pindolol und Antipyrin bei Patienten mit Lebererkrankungen. Schweiz Med Wochenschr 106: 1748–1750Google Scholar
  10. Ohnhaus EE, Münch U, Meier J (1982) Elimination of pindolol in liver disease. Eur J Clin Pharmacol 22: 247–251Google Scholar
  11. Sellers EM, Greenblatt DJ, Giles HC, Narango CA, Kaplan H, McLeod SM (1979) Chlordiazepoxide and oxazepam diposition in cirrhosis. Clin Pharmacol Ther 26: 240–246Google Scholar
  12. Shull HJ, Wilkinson GR, Johnson R, Schenker S (1976) Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 84: 420–425Google Scholar
  13. Sotaniemi EA, Anttila M, Pelkonen OR, Järvensivu P, Sundquist A (1979) Plasma clearance of propranolol and sotalol and hepatic drug metabolizing enzyme activity. Clin Pharmacol Ther 26: 153–161Google Scholar
  14. Tschanz C, Wilson RL, Shand DG (1983) The effects of cirrhosis on temazepam elimination. Clin Pharmacol Ther 33: 218Google Scholar
  15. Vesell ES (1979) The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 26: 275–286Google Scholar
  16. Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M (1977) Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 21: 301–309Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • N. R. Kitteringham
    • 1
  • L. Büstgens
    • 1
  • E. Brundert
    • 1
  • S. Mineshita
    • 1
  • E. E. Ohnhaus
    • 1
  1. 1.Abteilung für Allgemeine Innere MedizinMedizinische UniversitätsklinikEssenGermany

Personalised recommendations